{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:12:51Z","timestamp":1794366771304,"version":"4.9.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eururo.2026.01.014","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:58:22Z","timestamp":1768971502000},"page":"311-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting Prostatic Acid Phosphatase in Prostate Cancer: Roadmap on How To Venture Above and Beyond Prostate-specific Membrane Antigen with ACP3 Theranostics"],"prefix":"10.1016","volume":"89","author":[{"given":"Cristiano","family":"Pini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Gelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5806-1856","authenticated-orcid":false,"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.01.014_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.014_b0010","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00259-024-06852-1","article-title":"Cutting back on overdiagnosis \u2013 Occam\u2019s razor and unspecific bone uptakes in PSMA PET","volume":"51","author":"Pini","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.01.014_b0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/modpathol.2014.77","article-title":"Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer","volume":"28","author":"Queisser","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2026.01.014_b0020","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1007\/s00259-023-06287-0","article-title":"European guidelines update on PSMA PET\/CT for prostate cancer staging-snap back to reality","volume":"50","author":"Gelardi","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.01.014_b0025","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.7150\/thno.106574","article-title":"Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer \u2013 a systematic review and meta-analysis","volume":"15","author":"Ninatti","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2026.01.014_b0030","doi-asserted-by":"crossref","unstructured":"Backhaus P, Cazzamalli S, Oehler S, et al. Translational and first-in-human positron emission tomography targeting prostatic acid phosphatase in prostate cancer using the ligand [68Ga]Ga-OncoACP3-DOTA. Eur Urol 89;2026:305\u2013310. https:\/\/doi.org\/10.1016\/j.eururo.2025.11.025.","DOI":"10.1016\/j.eururo.2025.11.025"},{"key":"10.1016\/j.eururo.2026.01.014_b0035","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.01.014_b0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2024.09.036","article-title":"Novel radiopharmaceuticals and future of theranostics in genitourinary cancers","volume":"87","author":"Sollini","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:22:54Z","timestamp":1773872574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0302283826000205"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.014","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Prostatic Acid Phosphatase in Prostate Cancer: Roadmap on How To Venture Above and Beyond Prostate-specific Membrane Antigen with ACP3 Theranostics","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}